Default company panoramic image
Ee46b495 a709 4802 955f 694dc18c498d


Domainex seeks funding to allow it to conclude licensing discussions with a number of major pharmaceutical companies and build its pipeline.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Cambridge, England, GB
  • Currency USD
  • Founded January 2006
  • Employees 30
  • Website

Company Summary

Domainex provides drug discovery expertise to world-class pharmaceutical, biotechnology and academic clients while developing its own innovative cancer and immunology drugs on modest capital input.


  • Default avatar
    Keith Powell

    After working in Industrial Biotechnology with ICI, Keith had roles at Zeneca including Head of Discovery, Head of Biotechnology and finally Head of IP. He joined Maxygen in 1999 and led the development of the small-molecule business that was eventually spun out as Codexis. Since 2004 has worked with BBSF developing spin-out companies including Spear, Polytherics and Domainex. He has raised >$16 m VC funding and >$50m in partnering deals.

  • Default avatar
    Eddy Littler

    Eddy was head of the Molecular Sciences Unit at Wellcome with programmes in virology and cancer gene therapy and led projects through to phase II clinical trials. At GlaxoWellcome was head of antiviral research with programmes in hepatitis C virus, respiratory viruses and DNA vaccines . In 2001 became Medivir's Senior Director of Lead Discovery and was the lead scientist in the development and out licensing of programmes in hepatitis C and HIV.

  • Default avatar
    Trevor Perrior
    Director of Research

    Following academic research at Cambridge, Oxford and in the USA, Trevor held a number of senior R&D roles in the pharmaceutical and biotechnology companies ICI, AstraZeneca and Celltech. At Celltech he was Director of NCE Research and Head of Chemistry, with responsibility for leading the small-molecule research programmes against inflammation and oncology targets, and line management of a team of 100 medicinal and process chemists.

Previous Investors

  • Default avatar
    Longbow Capital, Bury Fitzwilliam-Lay and Partners, The Capital Fund